These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 7745993)

  • 21. Relationship between the response to influenza vaccination and the nutritional status in institutionalized elderly subjects.
    Fülöp T; Wagner JR; Khalil A; Weber J; Trottier L; Payette H
    J Gerontol A Biol Sci Med Sci; 1999 Feb; 54(2):M59-64. PubMed ID: 10051856
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunization with trivalent inactivated influenza vaccine in partially immunized toddlers.
    Englund JA; Walter EB; Gbadebo A; Monto AS; Zhu Y; Neuzil KM
    Pediatrics; 2006 Sep; 118(3):e579-85. PubMed ID: 16950949
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Annually repeated influenza vaccination improves humoral responses to several influenza virus strains in healthy elderly.
    de Bruijn IA; Remarque EJ; Beyer WE; le Cessie S; Masurel N; Ligthart GJ
    Vaccine; 1997; 15(12-13):1323-9. PubMed ID: 9302738
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Adjuvant use of the NKT cell agonist alpha-galactosylceramide leads to enhancement of M2-based DNA vaccine immunogenicity and protective immunity against influenza A virus.
    Fotouhi F; Shaffifar M; Farahmand B; Shirian S; Saeidi M; Tabarraei A; Gorji A; Ghaemi A
    Arch Virol; 2017 May; 162(5):1251-1260. PubMed ID: 28120096
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of zinc or zinc plus arginine supplementation on antibody titre and lymphocyte subsets after influenza vaccination in elderly subjects: a randomized controlled trial.
    Provinciali M; Montenovo A; Di Stefano G; Colombo M; Daghetta L; Cairati M; Veroni C; Cassino R; Della Torre F; Fabris N
    Age Ageing; 1998 Nov; 27(6):715-22. PubMed ID: 10408666
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Local and systemic immune response in nursing-home elderly following intranasal or intramuscular immunization with inactivated influenza vaccine.
    Muszkat M; Greenbaum E; Ben-Yehuda A; Oster M; Yeu'l E; Heimann S; Levy R; Friedman G; Zakay-Rones Z
    Vaccine; 2003 Mar; 21(11-12):1180-6. PubMed ID: 12559796
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison between a conventional subunit vaccine and the MF59-adjuvanted subunit influenza vaccine in the elderly: an evaluation of the safety, tolerability and immunogenicity.
    Sindoni D; La Fauci V; Squeri R; Cannavò G; Bacilieri S; Panatto D; Gasparini R; Amicizia D
    J Prev Med Hyg; 2009 Jun; 50(2):121-6. PubMed ID: 20099444
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Enhanced Influenza Virus-Like Particle Vaccination with a Structurally Optimized RIG-I Agonist as Adjuvant.
    Beljanski V; Chiang C; Kirchenbaum GA; Olagnier D; Bloom CE; Wong T; Haddad EK; Trautmann L; Ross TM; Hiscott J
    J Virol; 2015 Oct; 89(20):10612-24. PubMed ID: 26269188
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy, immunogenicity, and safety evaluation of an MF59-adjuvanted quadrivalent influenza virus vaccine compared with non-adjuvanted influenza vaccine in children: a multicentre, randomised controlled, observer-blinded, phase 3 trial.
    Vesikari T; Kirstein J; Devota Go G; Leav B; Ruzycky ME; Isakov L; de Bruijn M; Oberye J; Heijnen E
    Lancet Respir Med; 2018 May; 6(5):345-356. PubMed ID: 29631857
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of the safety and immunogenicity of an MF59®-adjuvanted with a non-adjuvanted seasonal influenza vaccine in elderly subjects.
    Frey SE; Reyes MR; Reynales H; Bermal NN; Nicolay U; Narasimhan V; Forleo-Neto E; Arora AK
    Vaccine; 2014 Sep; 32(39):5027-34. PubMed ID: 25045825
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antibody response to 1995-1996 influenza vaccine in institutionalized and non-institutionalized elderly women.
    Iorio AM; Alatri A; Camilloni B; Neri M; Baglio G; Donatelli I
    Gerontology; 1999; 45(1):31-8. PubMed ID: 9852378
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A randomised, single-blind, dose-range study to assess the immunogenicity and safety of a cell-culture-derived A/H1N1 influenza vaccine in adult and elderly populations.
    Hatz C; Cramer JP; Vertruyen A; Schwarz TF; von Sonnenburg F; Borkowski A; Lattanzi M; Hilbert AK; Cioppa GD; Leroux-Roels G
    Vaccine; 2012 Jul; 30(32):4820-7. PubMed ID: 22626675
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In vivo T cell activation, in vitro defective IL-2 secretion, and response to influenza vaccination in elderly women.
    Huang YP; Pechere JC; Michel M; Gauthey L; Loreto M; Curran JA; Michel JP
    J Immunol; 1992 Feb; 148(3):715-22. PubMed ID: 1730868
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of the reactogenicity and immunogenicity of a split and a subunit-adjuvanted influenza vaccine in elderly subjects.
    Squarcione S; Sgricia S; Biasio LR; Perinetti E
    Vaccine; 2003 Mar; 21(11-12):1268-74. PubMed ID: 12559808
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety and immunogenicity of an MF59(®)-adjuvanted A/H5N1 pre-pandemic influenza vaccine in adults and the elderly.
    Vesikari T; Forstén A; Herbinger KH; Cioppa GD; Beygo J; Borkowski A; Groth N; Bennati M; von Sonnenburg F
    Vaccine; 2012 Feb; 30(7):1388-96. PubMed ID: 22192847
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Negative Effect of Age, but Not of Latent Cytomegalovirus Infection on the Antibody Response to a Novel Influenza Vaccine Strain in Healthy Adults.
    van den Berg SPH; Wong A; Hendriks M; Jacobi RHJ; van Baarle D; van Beek J
    Front Immunol; 2018; 9():82. PubMed ID: 29434600
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A phase II, randomised clinical trial to demonstrate the non-inferiority of low-dose MF59-adjuvanted pre-pandemic A/H5N1 influenza vaccine in adult and elderly subjects.
    Czajka H; Unal S; Ulusoy S; Usluer G; Strus A; Sennaroglu E; Guzik J; Topeli Iskit A; Dargiewicz A; Musial D; Caylan R; Dziduch J; Eskioglu E; Hasiec B; Cwinarowiczliwa E; Belli R; Abdel-Messih IA; Beygo J; Fragapane E
    J Prev Med Hyg; 2012 Sep; 53(3):136-42. PubMed ID: 23362618
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Vaccines with MF59 adjuvant expand the antibody repertoire to target protective sites of pandemic avian H5N1 influenza virus.
    Khurana S; Chearwae W; Castellino F; Manischewitz J; King LR; Honorkiewicz A; Rock MT; Edwards KM; Del Giudice G; Rappuoli R; Golding H
    Sci Transl Med; 2010 Jan; 2(15):15ra5. PubMed ID: 20371470
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Virus-like particle (VLP) vaccine conferred complete protection against a lethal influenza virus challenge.
    Galarza JM; Latham T; Cupo A
    Viral Immunol; 2005; 18(1):244-51. PubMed ID: 15802970
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safety and immunogenicity of an inactivated subunit influenza virus vaccine combined with MF59 adjuvant emulsion in elderly subjects, immunized for three consecutive influenza seasons.
    Minutello M; Senatore F; Cecchinelli G; Bianchi M; Andreani T; Podda A; Crovari P
    Vaccine; 1999 Jan; 17(2):99-104. PubMed ID: 9987141
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.